Dr. Bauml Discusses Immunotherapy in Head and Neck Cancer

Joshua Bauml, MD, assistant professor, Perelman School of Medicine, University of Pennsylvania, discusses immunotherapy in head and neck cancer.

Bauml says that immunotherapy has a key role to play in the treatment of head and neck cancer. The arrival of PD-1 inhibitors, especially for patients with metastatic disease, has brought promise to the treatment landscape.

Specifically, Bauml says, head and neck cancer has overregulation of PD-L1 and PD-L2, as well as being virally mediated, making it an appropriate setting for immunotherapy.